Corvus Pharmaceuticals reported a significant increase in net loss to $52.0 million for the nine months ended September 30, 2026, compared to $3.0 million in the prior year, primarily driven by a $21.1 million increase in research and development expenses. The company's cash position strengthened considerably to $203.0 million in cash and marketable securities following a follow-on public offering that raised $189.4 million.
Corvus Pharmaceuticals reported third quarter 2026 financial results and provided a business update on its soquelitinib clinical programs. The company ended the quarter with $202.9 million in cash and marketable securities, which is expected to provide a financial runway into the second quarter of 2028.
“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib. Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial. We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027. We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial. Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”
Richard A. Miller, M.D., co-founder, president and chief executive officer